These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 28814738)
61. Natural metabolites of 1alpha,25-dihydroxyvitamin D(3) retain biologic activity mediated through the vitamin D receptor. Harant H; Spinner D; Reddy GS; Lindley IJ J Cell Biochem; 2000 Apr; 78(1):112-20. PubMed ID: 10797570 [TBL] [Abstract][Full Text] [Related]
62. Design, synthesis and biological evaluation of non-secosteriodal vitamin D receptor ligand bearing double side chain for the treatment of chronic pancreatitis. Kang ZS; Wang C; Han XL; Du JJ; Li YY; Zhang C Eur J Med Chem; 2018 Feb; 146():541-553. PubMed ID: 29407979 [TBL] [Abstract][Full Text] [Related]
63. Targeted ablation of the 25-hydroxyvitamin D 1alpha -hydroxylase enzyme: evidence for skeletal, reproductive, and immune dysfunction. Panda DK; Miao D; Tremblay ML; Sirois J; Farookhi R; Hendy GN; Goltzman D Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7498-503. PubMed ID: 11416220 [TBL] [Abstract][Full Text] [Related]
64. Positive and negative regulations of the renal 25-hydroxyvitamin D3 1alpha-hydroxylase gene by parathyroid hormone, calcitonin, and 1alpha,25(OH)2D3 in intact animals. Murayama A; Takeyama K; Kitanaka S; Kodera Y; Kawaguchi Y; Hosoya T; Kato S Endocrinology; 1999 May; 140(5):2224-31. PubMed ID: 10218975 [TBL] [Abstract][Full Text] [Related]
65. Effects of alkyl side chains and terminal hydrophilicity on vitamin D receptor (VDR) agonistic activity based on the diphenylpentane skeleton. Misawa T; Yorioka M; Demizu Y; Noguchi-Yachide T; Ohoka N; Kurashima-Kinoshita M; Motoyoshi H; Nojiri H; Kittaka A; Makishima M; Naito M; Kurihara M Bioorg Med Chem Lett; 2015 Nov; 25(22):5362-6. PubMed ID: 26432035 [TBL] [Abstract][Full Text] [Related]
66. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Sochorová K; Budinský V; Rozková D; Tobiasová Z; Dusilová-Sulková S; Spísek R; Bartůnková J Clin Immunol; 2009 Oct; 133(1):69-77. PubMed ID: 19660988 [TBL] [Abstract][Full Text] [Related]
67. Creation of Potent Vitamin D Receptor Agonists and Antagonists with 2α-(ω-Hydroxyalkylation) Concept to the seco-Steroid Skeleton. Kittaka A Chimia (Aarau); 2018 Dec; 72(12):859-865. PubMed ID: 30648951 [TBL] [Abstract][Full Text] [Related]
77. PT19c, Another Nonhypercalcemic Vitamin D2 Derivative, Demonstrates Antitumor Efficacy in Epithelial Ovarian and Endometrial Cancer Models. Kawar N; Maclaughlan S; Horan TC; Uzun A; Lange TS; Kim KK; Hopson R; Singh AP; Sidhu PS; Glass KA; Shaw S; Padbury JF; Vorsa N; Arnold LA; Moore RG; Brard L; Singh RK Genes Cancer; 2013 Nov; 4(11-12):524-34. PubMed ID: 24386512 [TBL] [Abstract][Full Text] [Related]
78. Vitamin D receptor agonists target CXCL10: new therapeutic tools for resolution of inflammation. Scolletta S; Colletti M; Di Luigi L; Crescioli C Mediators Inflamm; 2013; 2013():876319. PubMed ID: 23690671 [TBL] [Abstract][Full Text] [Related]
79. Selective knockout of the vitamin d receptor in the heart results in cardiac hypertrophy: is the heart a drugable target for vitamin D receptor agonists? Simpson RU Circulation; 2011 Oct; 124(17):1808-10. PubMed ID: 22025636 [No Abstract] [Full Text] [Related]
80. Correction of vitamin D status by calcidiol: pharmacokinetic profile, safety, and biochemical effects on bone and mineral metabolism of daily and weekly dosage regimens. Minisola S; Cianferotti L; Biondi P; Cipriani C; Fossi C; Franceschelli F; Giusti F; Leoncini G; Pepe J; Bischoff-Ferrari HA; Brandi ML Osteoporos Int; 2017 Nov; 28(11):3239-3249. PubMed ID: 28815282 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]